No news on Pfizer’s Covid-19 vaccine is good news — and bad news
Pfizer and BioNTech are under a white-hot spotlight because their vaccine, by design, is likely to be the first to have any efficacy data.
Pfizer and BioNTech are under a white-hot spotlight because their vaccine, by design, is likely to be the first to have any efficacy data.
Spending on GLP-1 drugs has quickly surpassed spending on insulin products in the last few years.
The plans for a broader rollout of the AI tool comes nearly a year after the 184-hospital chain piloted it at a handful ER departments.
The USDA will instead enforce a limit on added sugars in chocolate and other flavored milk served in schools starting in the fall of 2025.
The authors of a new study argue the heralded arrival of biosimilars failed to fully deliver on their promise.
Costs for the U.S. health care system and the federal government will climb thanks to weight loss drugs, two new reports show.
Novo Nordisk’s move to discontinue its Levemir insulin has left patients to “pick up the pieces.”
The first signs that H5N1 avian flu was starting to spread from person to person would trigger a race to produce massive amounts of vaccine.
A simple blood test to detect colorectal cancer sounds amazing. But unlike colonoscopy, a blood test can’t remove precancerous polyps.
The agency simply doesn’t have enough resources to challenge but 1% of hospital mergers, so they continue to result in less competition and higher prices.
One goal of freeing med students from the burden of student debt is to enable them to go into primary care or work in underserved…